Free Trial
OTCMKTS:ENZN

Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis

Enzon Pharmaceuticals logo
$0.08 0.00 (-3.53%)
As of 08/8/2025 03:58 PM Eastern

About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN)

Key Stats

Today's Range
$0.08
$0.08
50-Day Range
$0.06
$0.13
52-Week Range
$0.06
$0.24
Volume
7,558 shs
Average Volume
55,727 shs
Market Capitalization
$6.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ENZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENZN Stock News Headlines

Enzon Pharmaceuticals, Inc. (ENZN) - Yahoo Finance
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”
Enzon and Viskase Enter into Merger Agreement
ENZN Enzon Pharmaceuticals, Inc.
See More Headlines

ENZN Stock Analysis - Frequently Asked Questions

Enzon Pharmaceuticals' stock was trading at $0.1561 at the start of the year. Since then, ENZN stock has decreased by 47.5% and is now trading at $0.0820.

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) released its quarterly earnings data on Friday, May, 9th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter.

Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzon Pharmaceuticals investors own include Biocept (BIOC), Aeterna Zentaris (AEZS), Energy Transfer (ET), DURECT (DRRX), Nymox Pharmaceutical (NYMX), OpGen (OPGN) and BioCryst Pharmaceuticals (BCRX).

Company Calendar

Last Earnings
5/09/2025
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:ENZN
Previous Symbol
NASDAQ:ENZN
CIK
727510
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$780 thousand
Net Margins
N/A
Pretax Margin
1,150.00%
Return on Equity
-22.19%
Return on Assets
-1.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
82.17
Quick Ratio
82.17

Sales & Book Value

Annual Sales
$30 thousand
Price / Sales
202.84
Cash Flow
$0.01 per share
Price / Cash Flow
8.11
Book Value
$0.04 per share
Price / Book
2.05

Miscellaneous

Outstanding Shares
74,210,000
Free Float
73,918,000
Market Cap
$6.09 million
Optionable
Not Optionable
Beta
0.30

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (OTCMKTS:ENZN) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners